Brown tumor

Last updated
Brown tumor
Brown tumours of the hands.jpg
Brown tumours of the hands in a patient with hyperparathyroidism.

The brown tumor is a bone lesion that arises in settings of excess osteoclast activity, such as hyperparathyroidism. They are a form of osteitis fibrosa cystica. It is not a neoplasm, but rather simply a mass. It most commonly affects the maxilla and mandible, though any bone may be affected. [1] Brown tumours are radiolucent on x-ray.

Contents

Pathology

Micrograph of a brown tumor (left of image). H&E stain. Brown tumour - low mag.jpg
Micrograph of a brown tumor (left of image). H&E stain.

Brown tumours consist of fibrous tissue, woven bone and supporting vasculature, but no matrix. The osteoclasts consume the trabecular bone that osteoblasts lay down and this front of reparative bone deposition followed by additional resorption can expand beyond the usual shape of the bone, involving the periosteum thus causing bone pain. The characteristic brown coloration results from hemosiderin deposition into the osteolytic cysts. Hemosiderin deposition is not a distinctive feature of brown tumors; it may also be seen in giant cell tumors of the bone. [2] [3]

Brown tumors may be rarely associated with ectopic parathyroid adenomas [4] or end stage renal osteodystrophy. [5]

Diagnosis

Histologically, it is impossible to distinguish a Brown tumor of hyperparathyroidism from other giant cell lesions of bone. Rarely a focal collection of osteoclasts (brown tumor) may occur in relation to periosteum and be indistinguishable from a peripheral giant cell granuloma (giant cell epulis). The possibility of hyperparathyroidism should be considered in patients with recurrent or multiple giant cell epulides. [6]

Radiographically, brown tumor may show no detectable changes or a generalized osteoporosis. Partial loss of lamina dura around the teeth may occur but is not a constant feature. Focal Lesions (Brown Tumor) present as sharply defined, round or oval radiolucent areas which may appear multilocular. Such lesions occur more frequently in mandible than maxilla [6]

Treatment

Treatment of hyperparathyroidism is required. Parathyroidectomy usually leads to spontaneous healing of Brown tumors in primary cases. [7] Calcitriol (Rocaltrol) and cinacalcet (a calcimimetic) are used as pharmacologic treatments. [8] [9]

Epidemiology

Age and gender have an effect on the incidence of these lesions; they are more prevalent in women than men (though still common in both genders), and they appear more frequently with age. Due to the standard of medical care and screening in developed countries, it is increasingly rare for primary hyperparathyroidism to present with accompanying bone disease. This is not the case in less developed nations, however, and the two conditions are more often seen together. [10]

See also

Related Research Articles

<span class="mw-page-title-main">Parathyroid hormone</span> Mammalian protein found in Homo sapiens

Parathyroid hormone (PTH), also called parathormone or parathyrin, is a peptide hormone secreted by the parathyroid glands that regulates the serum calcium concentration through its effects on bone, kidney, and intestine.

<span class="mw-page-title-main">Osteoclast</span> Cells that breaks the bone tissues

An osteoclast is a type of bone cell that breaks down bone tissue. This function is critical in the maintenance, repair, and remodeling of bones of the vertebral skeleton. The osteoclast disassembles and digests the composite of hydrated protein and mineral at a molecular level by secreting acid and a collagenase, a process known as bone resorption. This process also helps regulate the level of blood calcium.

<span class="mw-page-title-main">Parathyroid chief cell</span>

Parathyroid chief cells are one of the two cell types of the parathyroid glands, along with oxyphil cells. The chief cells are much more prevalent in the parathyroid gland than the oxyphil cells. It is perceived that oxyphil cells may be derived from chief cells at puberty, as they are not present at birth like chief cells.

<span class="mw-page-title-main">Hyperparathyroidism</span> Increase in parathyroid hormone levels in the blood

Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. This occurs from a disorder either within the parathyroid glands or as response to external stimuli. Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream in response to increased production of parathyroid hormone. In healthy people, when blood calcium levels are high, parathyroid hormone levels should be low. With long-standing hyperparathyroidism, the most common symptom is kidney stones. Other symptoms may include bone pain, weakness, depression, confusion, and increased urination. Both primary and secondary may result in osteoporosis.

<span class="mw-page-title-main">Parathyroidectomy</span> Surgical removal of one or more of the parathyroid glands

Parathyroidectomy is the surgical removal of one or more of the (usually) four parathyroid glands. This procedure is used to remove an adenoma or hyperplasia of these glands when they are producing excessive parathyroid hormone (PTH): hyperparathyroidism. The glands are usually four in number and located adjacent to the posterior surface of the thyroid gland, but their exact location is variable. When an elevated PTH level is found, a sestamibi scan or an ultrasound may be performed in order to confirm the presence and location of abnormal parathyroid tissue.

<span class="mw-page-title-main">Benign tumor</span> Mass of cells which cannot spread throughout the body

A benign tumor is a mass of cells (tumor) that does not invade neighboring tissue or metastasize. Compared to malignant (cancerous) tumors, benign tumors generally have a slower growth rate. Benign tumors have relatively well differentiated cells. They are often surrounded by an outer surface or stay contained within the epithelium. Common examples of benign tumors include moles and uterine fibroids.

<span class="mw-page-title-main">Primary hyperparathyroidism</span> Medical condition

Primary hyperparathyroidism is a medical condition where the parathyroid gland produce excess amounts of parathyroid hormone (PTH). The symptoms of the condition relate to the resulting elevated serum calcium (hypercalcemia), which can cause digestive symptoms, kidney stones, psychiatric abnormalities, and bone disease.

<span class="mw-page-title-main">Multiple endocrine neoplasia type 1</span> Medical condition

Multiple endocrine neoplasia type 1 (MEN-1) is one of a group of disorders, the multiple endocrine neoplasias, that affect the endocrine system through development of neoplastic lesions in pituitary, parathyroid gland and pancreas. Individuals suffering from this disorder are prone to developing multiple endocrine and nonendocrine tumors. It was first described by Paul Wermer in 1954.

<span class="mw-page-title-main">Giant-cell tumor of bone</span> Medical condition

Giant-cell tumor of the bone (GCTOB), is a relatively uncommon tumor of the bone. It is characterized by the presence of multinucleated giant cells. Malignancy in giant-cell tumor is uncommon and occurs in about 2% of all cases. However, if malignant degeneration does occur, it is likely to metastasize to the lungs. Giant-cell tumors are normally benign, with unpredictable behavior. It is a heterogeneous tumor composed of three different cell populations. The giant-cell tumour stromal cells (GCTSC) constitute the neoplastic cells, which are from an osteoblastic origin and are classified based on expression of osteoblast cell markers such as alkaline phosphatase and osteocalcin. In contrast, the mononuclear histiocytic cells (MNHC) and multinucleated giant cell (MNGC) fractions are secondarily recruited and comprise the non-neoplastic cell population. They are derived from an osteoclast-monocyte lineage determined primarily by expression of CD68, a marker for monocytic precursor cells. In most patients, the tumors are slow to develop, but may recur locally in as many as 50% of cases.

<span class="mw-page-title-main">Osteitis fibrosa cystica</span> Medical condition

Osteitis fibrosa cystica is a skeletal disorder resulting in a loss of bone mass, a weakening of the bones as their calcified supporting structures are replaced with fibrous tissue, and the formation of cyst-like brown tumors in and around the bone. Osteitis fibrosis cystica (OFC), also known as osteitis fibrosa, osteodystrophia fibrosa, and von Recklinghausen's disease of bone, is caused by hyperparathyroidism, which is a surplus of parathyroid hormone from over-active parathyroid glands. This surplus stimulates the activity of osteoclasts, cells that break down bone, in a process known as osteoclastic bone resorption. The hyperparathyroidism can be triggered by a parathyroid adenoma, hereditary factors, parathyroid carcinoma, or renal osteodystrophy. Osteoclastic bone resorption releases minerals, including calcium, from the bone into the bloodstream, causing both elevated blood calcium levels, and the structural changes which weaken the bone. The symptoms of the disease are the consequences of both the general softening of the bones and the excess calcium in the blood, and include bone fractures, kidney stones, nausea, moth-eaten appearance in the bones, appetite loss, and weight loss.

<span class="mw-page-title-main">Tertiary hyperparathyroidism</span> Medical condition

Tertiary hyperparathyroidism is a condition involving the overproduction of the hormone, parathyroid hormone, produced by the parathyroid glands. The parathyroid glands are involved in monitoring and regulating blood calcium levels and respond by either producing or ceasing to produce parathyroid hormone. Anatomically, these glands are located in the neck, para-lateral to the thyroid gland, which does not have any influence in the production of parathyroid hormone. Parathyroid hormone is released by the parathyroid glands in response to low blood calcium circulation. Persistent low levels of circulating calcium are thought to be the catalyst in the progressive development of adenoma, in the parathyroid glands resulting in primary hyperparathyroidism. While primary hyperparathyroidism is the most common form of this condition, secondary and tertiary are thought to result due to chronic kidney disease (CKD). Estimates of CKD prevalence in the global community range from 11 to 13% which translate to a large portion of the global population at risk of developing tertiary hyperparathyroidism. Tertiary hyperparathyroidism was first described in the late 1960s and had been misdiagnosed as primary prior to this. Unlike primary hyperparathyroidism, the tertiary form presents as a progressive stage of resolved secondary hyperparathyroidism with biochemical hallmarks that include elevated calcium ion levels in the blood, hypercalcemia, along with autonomous production of parathyroid hormone and adenoma in all four parathyroid glands. Upon diagnosis treatment of tertiary hyperparathyroidism usually leads to a surgical intervention.

<span class="mw-page-title-main">Central giant-cell granuloma</span> Medical condition

Central giant-cell granuloma (CGCG) is a localised benign condition of the jaws. It is twice as common in females and is more likely to occur before age 30. Central giant-cell granulomas are more common in the anterior mandible, often crossing the midline and causing painless swellings.

<span class="mw-page-title-main">Endocrine disease</span> Medical condition

Endocrine diseases are disorders of the endocrine system. The branch of medicine associated with endocrine disorders is known as endocrinology.

Bone disease refers to the medical conditions which affect the bone.

<span class="mw-page-title-main">CDC73</span> Protein-coding gene in the species Homo sapiens

Cell division cycle 73, Paf1/RNA polymerase II complex component, homolog , also known as CDC73 and parafibromin, is a protein which in humans is encoded by the CDC73 gene.

<span class="mw-page-title-main">Parathyroid adenoma</span> Medical condition

A parathyroid adenoma is a benign tumor of the parathyroid gland. It generally causes hyperparathyroidism; there are very few reports of parathyroid adenomas that were not associated with hyperparathyroidism.

<span class="mw-page-title-main">Parathyroid carcinoma</span> Medical condition

Parathyroid carcinoma is a rare cancer resulting in parathyroid adenoma to carcinoma progression. It forms in tissues of one or more of the parathyroid glands.

An endocrine bone disease is a bone disease associated with a disorder of the endocrine system. An example is osteitis fibrosa cystica.

<span class="mw-page-title-main">Parathyroid disease</span> Medical condition

Many conditions are associated with disorders of the function of the parathyroid gland. Some disorders may be purely anatomical resulting in an enlarged gland which will raise concern. Such benign disorders, such as parathyroid cyst, are not discussed here. Parathyroid diseases can be divided into those causing hyperparathyroidism, and those causing hypoparathyroidism.

<span class="mw-page-title-main">Sestamibi parathyroid scan</span> Procedure in nuclear medicine

A sestamibi parathyroid scan is a procedure in nuclear medicine which is performed to localize parathyroid adenoma, which causes Hyperparathyroidism. Adequate localization of parathyroid adenoma allows the surgeon to use a minimally invasive surgical approach.

References

  1. Meydan N, Barutca S, Guney E, Boylu S, Savk O, Culhaci N, Ayhan M (June 2006). "Brown tumors mimicking bone metastases". Journal of the National Medical Association. 98 (6): 950–3. PMC   2569361 . PMID   16775919.
  2. Aoki J, Moriya K, Yamashita K, Fujioka F, Ishii K, Karakida O, et al. (1991). "Giant cell tumors of bone containing large amounts of hemosiderin: MR-pathologic correlation". Journal of Computer Assisted Tomography. 15 (6): 1024–7. doi:10.1097/00004728-199111000-00023. PMID   1939753.
  3. Matsushige T, Nakaoka M, Yahara K, Kagawa K, Miura H, Ohnuma H, Kurisu K (August 2008). "Giant cell tumor of the temporal bone with intratumoral hemorrhage". Journal of Clinical Neuroscience. 15 (8): 923–7. doi:10.1016/j.jocn.2007.03.013. PMID   18554912. S2CID   37272951.
  4. Mohan M, Neelakandan RS, Siddharth D, Sharma R (October 2013). "An unusual case of brown tumor of hyperparathyroidism associated with ectopic parathyroid adenoma". European Journal of Dentistry. 7 (4): 500–503. doi:10.4103/1305-7456.120657. PMC   4053678 . PMID   24932128.
  5. Nassar GM, Ayus JC (November 1999). "Images in clinical medicine. Brown tumor in end-stage renal disease". The New England Journal of Medicine. 341 (22): 1652. doi:10.1056/nejm199911253412204. PMID   10572153.
  6. 1 2 Johannessen AC (December 2005). "Oral pathology, 4th edition". European Journal of Orthodontics (Book review). 27 (6): 615–616. doi: 10.1093/ejo/cji104 .; Soames JV, Southam JC (2005). Clinical facial analysis. Elements, principles and techniques. Heidelberg, Germany: Springer-Verlag GmbH. ISBN   978-0-19-852794-7.
  7. Marcocci C, Cianferotti L, Cetani F (October 2012). "Bone disease in primary hyperparathyrodism". Therapeutic Advances in Musculoskeletal Disease. 4 (5): 357–68. doi:10.1177/1759720X12441869. PMC   3458615 . PMID   23024712.
  8. Sprenger-Mähr H, Zitt E, Kronbichler A, Cejna M, Lhotta K (November 2019). "A hemodialysis patient with bone disease after pregnancy: a case report". BMC Nephrology. 20 (1): 425. doi:10.1186/s12882-019-1603-8. PMC   6873679 . PMID   31752733.
  9. Eroglu E, Kontas ME, Kocyigit I, Kontas O, Donmez H, Kucuk A, et al. (November 2019). "Brown tumor of the thoracic spine presenting with paraplegia in a patient with peritoneal dialysis". CEN Case Reports. 8 (4): 227–232. doi:10.1007/s13730-019-00398-0. PMC   6820650 . PMID   31089951.
  10. "Brown Tumor". BoneTumor.org.